NewAmsterdam Pharma N.V.
NAMS | NASDAQ
$20.06
-$0.70 (-3.37%)
At close: Oct 30, 2026, 4:00 PM ET
$20.56
+$0.50 (+2.50%)
Pre-market:
Nov 2, 2026, 7:02 AM ET
Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Key Executives
| Name | Position |
|---|---|
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director |
| Douglas F. Kling | Chief Operating Officer |
| Maryellen McQuade | Chief People Officer |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Michael F. Marino | Chief Legal Officer & Corporate Secretary |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations |
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Juliette Audet | Chief Strategy & Business Officer |
| Louise Kooij | Chief Accounting Officer |
| Marc Ditmarsch | Chief Development Officer |
| Matthew Philippe | Executive VP & Head of Investor Relations |
| Robert W. Gunning CGMA | Principal Accounting Officer, VP & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | 4 | Filing |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 22, 2026 | SC 13D/A | [Amend] Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 14, 2026 | 8-K/A | [Amend] Current Report |
| Aug 14, 2026 | 3 | Filing |
NewAmsterdam Pharma N.V.
| Country | Netherlands |
| IPO Date | Feb 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Michael Harvey Davidson Facp. |
Contact Details
Gooimeer 2-35 Naarden,
New Hampshire 1411 DC Netherlands
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| CUSIP Number | n/a |
| ISIN Number | NL00150012L7 |
| SIC Code | 2834 |
Recent News
- 1 month ago / globenewswire.comNewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
- 1 month ago / prnewswire.comMenarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
- 1 month ago / globenewswire.comNewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- 2 months ago / globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 2 months ago / globenewswire.comNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
- 2 months ago / globenewswire.comNewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
- 3 months ago / marketbeat.comNewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
- 3 months ago / zacks.comNewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
- 3 months ago / globenewswire.comNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
- 3 months ago / globenewswire.comNewAmsterdam Pharma to Host Investor Day on August 5, 2026
Add to Watchlist
Select watchlists to add or remove NAMS